Covaxin neutralises both Alpha, Delta variants of Covid effectively, research by top US health institute finds

The vaccine has so far been given to around 25 million recipients in India and elsewhere. Interim results from Covaxin's Phase 3 trial have reportedly shown over "78% efficacy against symptomatic disease, 100% efficacy against severe infection and 70% efficacy against asymptomatic infection."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3w5CDbw
via IFTTT